ZYNE News and Press, Zynerba Pharmaceuticals Inc. From 03/07/23

DEVON, Pa, March 07, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of ...

DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of...

Zynerba Pharmaceuticals ( NASDAQ: ZYNE ) said on Wednesday a comprehensive data review showed its therapy, Zygel, could treat Fragile X syndrome (FXS) based on the central role the endocannabinoid system in neuronal development and function. The company said cannabidiol could...

Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS) Cannabidiol may help restore the function of the ECS in FXS patients according to review of data ...

Zynerba Pharmaceuticals ( NASDAQ: ZYNE ) says top-line data for a phase 3 trial of its Fragile X syndrome treatment Zygel will now come in H1 2024 instead of H2 2023. The company said that high rates of respiratory syncytial virus and influenza as well as the continued impact of COVID...

RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic” (high rates of RSV, influenza and COVID-19); topline results now expected first half of 2024 Cash runway extended to mid-year 2024 due to prioritization ...

Zygel™ achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment DEVON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: Z...

DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 61 st Annual M...

Study finds patients with Fragile X who have a highly methylated FMR1 gene that were treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with placebo Topline results from follow-on RECONNECT confirmatory pivotal Phase 3 trial of Zyg...

The European Commission (EC) granted orphan drug designation to Zynerba Pharmaceuticals' ( NASDAQ: ZYNE ) cannabidiol, the active ingredient in the company's transdermal gel Zygel, to treat 22q11.2 deletion syndrome (22q). The 22q11.2 deletion syndrome is a disord...